Innovative combination of medetomidine and vatinoxan helps minimize unwanted cardiovascular side effects while preserving reliable sedation and analgesia.
Dogs should be monitored frequently during sedation for changes in heart rate, blood pressure, respiratory rate and body temperature.
|
Zenalpha® helps improve the sedation monitoring experience for the veterinary team as it keeps the patient’s heart rate and blood pressure closer to normal.
Do not use Zenalpha® in dogs with cardiac disease, respiratory disorders, shock, severe debilitation, that have hypoglycemia or are at risk of developing hypoglycemia, or are stressed due to extreme heat, cold or fatigue.
|
| Less stress for veterinary teams – reduced time to complete procedures and sending dogs home sooner can give veterinary teams time back in their day.
|
Zenalpha® offers a short time to onset (5-15 minutes) and a short duration of sedation (~45 minutes) in most dog
Zenalpha® should not be administered in the presence of pre-existing hypotension, hypoxia or bradycardia.
|
Increases procedural efficiency and is effective for a broad range of procedures
Due to the pronounced cardiovascular effects of alpha-2 adrenoceptor agonists, only clinically healthy dogs (American Society of Anesthesiologists [ASA] classes I and II) should be administered Zenalpha®.
|
| Each mL contains 0.5 mg medetomidine hydrochloride and 10 mg vatinoxan hydrochloride
|
| Zenalpha® is available in 10 mL multi-dose glass vials.
|
| For intramuscular (IM) injection in dogs only.
|
